Pregabalin 150 mg Capsule
Pregabalin 150mg
Prescription medication
Highfield Life Science Co., Ltd.
MFDS item code 201905825 · Approved 2019.08.19
This product's status changed to Approval withdrawn on 2024.03.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used to relieve peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive treatment for partial seizures with or without secondary generalized symptoms in the treatment of epilepsy in adults. Additionally, it helps improve the symptoms of fibromyalgia. It is effectively used for various nerve-related diseases and pain management.
This medicine is administered orally, with or without food, in 2 divided doses of the total daily dose of pregabalin. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the individual patient’s response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis. (Approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: Supplemental dose refers to a dose administered once in addition. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Administration is not recommended for children under 12 years of age or adolescent patients aged 12 ~17 years because sufficient safety and efficacy data are not available.
This medication may increase the risk of suicidal thoughts or actions; therefore, if any mood changes or symptoms of depression occur during treatment, the patient must immediately inform their healthcare provider. Patients with hypersensitivity to this drug or certain genetic issues such as lactose intolerance should not take this medication. Diabetic patients should exercise caution as weight gain may necessitate adjustments in blood sugar control medications. If symptoms of angioedema (swelling of face or around the mouth) occur, discontinue use immediately. Elderly patients should be cautious, as this medication may increase the risk of falls due to dizziness or drowsiness. Temporary visual disturbances or changes in vision may occur, so consult a healthcare provider if these symptoms appear. Abrupt discontinuation of this drug may lead to withdrawal symptoms such as insomnia, headache, and anxiety; the dosage should be tapered off according to healthcare provider recommendations. Due to the risk of drug abuse, patients with a history of drug abuse or mental disorders must consult before taking this medication. Patients with impaired kidney function may require dosage adjustments. Patients with heart disease should be cautious, as symptoms of heart failure may worsen with this medication. Taking this medication with opioids increases the risk of central nervous system depression, so follow the doctor's advice closely. Patients with respiratory conditions, renal impairment, or the elderly may be at higher risk for severe respiratory depression and should be monitored. During early pregnancy, there is a risk of fetal malformations; thus, pregnant women should avoid taking this medication or do so very cautiously, and women of childbearing potential should use effective contraceptive methods. Breastfeeding women should discuss with their healthcare provider whether to continue or stop breastfeeding, as this medication can pass into breast milk. Driving or operating machinery may increase the risk of accidents due to dizziness or drowsiness after taking this medication, so caution is advised. Severe skin reactions (such as Stevens-Johnson syndrome) may occur, and if any rash or unusual symptoms develop, the patient should stop taking it immediately and notify their healthcare provider. This medication has little drug interaction; however, caution is needed when taking it with central nervous system depressants. In case of overdose, symptoms such as drowsiness, confusion, depression, seizures may occur, and immediate medical attention should be sought.
suicidal impulse, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, edema around the mouth, upper airway edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorder, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like syndrome, restlessness, depression, pain, sweating, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, anorexia, hypoglycemia, confusion, disorientation, irritability, euphoria, decreased libido, insomnia, depersonalization, hypersexuality, restlessness, anxiety, mood swings, emotional blunting, elevated mood, difficulty finding appropriate terms, hallucinations, abnormal dreams, increased libido, panic attacks, inability to inhibit, apathy, dizziness, drowsiness, ataxia, motor coordination abnormalities, balance disturbances, amnesia, attention deficits, memory impairments, tremors, dysarthria, sensory abnormalities, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, speech disorders, myotonia, reflex reduction, motor abnormalities, psychomotor agitation, position-related dizziness, hypersensitivity, burning sensation, activity tremors, syncope, confusion, hypokinesia, olfactory abnormalities, taste loss, writing disability, blurred vision, diplopia, indirect visual loss, visual disturbances, visual field defects, photopsia, dry eyes, ocular swelling, decreased vision, eye pain, eye fatigue, increased tear production, eye irritation, mydriasis, vibrotactile perception changes in depth of vision, strabismus, brightness of vision, vertigo, audi hypersensitivity, first-degree atrioventricular block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, nasal bleeding, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory suppression, vomiting, abdominal distension, constipation, dry mouth, bloating, hypersalivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle stiffness, rhabdomyolysis, urinary dysfunction, urinary incontinence, reduced urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, nipple discharge, gynecomastia, peripheral edema, edema, gait abnormalities, falling, feeling drunk, altered sensation, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, elevated serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, elevated blood creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, shock, anaphylaxis-like symptoms, skin and mucous membrane syndrome, erythema multiforme, delirium, paralysis, affective disorder, agitation, seizures, coma, death
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. It is best kept at room temperature between 15 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness and safety.
A hard capsule with a white upper half and a white lower half containing a white powder that is white or light yellow in color.
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 150mg
Prescription medication
Highfield Life Science Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.